学术周报 · IF≥10
骨科领域文献阅读汇编
2026年第44周 (2026-10-31) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Journal of advanced research | 2 | IF 17.1 |
| Science bulletin | 1 | IF 20.7 |
| Cell | 1 | IF 45.1 |
| Journal of sport and health science | 1 | IF 13.1 |
| Science translational medicine | 1 | IF 15.6 |
| Nature biomedical engineering | 1 | IF 26.3 |
| Diabetes care | 1 | IF 22.6 |
| Journal of hazardous materials | 1 | IF 10.6 |
| Annals of the rheumatic diseases | 1 | IF 24.0 |
| JAMA internal medicine | 1 | IF 26.3 |
1骨质疏松/骨代谢 (4篇)
临床研究 (1篇)
Mesenchymal stem/stromal cells (MSCs) are osteoregenerative; however, their therapeutic efficacy for skeletal conditions is hampered by poor bone-homing ("osteotropism"). In preclinical models, this deficit is correctable by MSC glycocalyx editing to enforce sialylated Lewis X (sLeX) expression, thereby programming osteotropism. We conducted a first-in-human clinical trial (ClinicalTrials.gov: NCT02566655) involving a single intravenous infusion of glycocalyx-edited autologous bone marrow-derived MSCs in ten women with advanced-stage osteoporosis. The protocol-mandated evaluation spanned 2 years and included clinical assessments, radiographic studies, and measurements of bone turnover markers (BTMs), bone tissue area (BTA), and bone mineral density (BMD). Thereafter, fracture and safety monitoring continued for >3 additional years for each patient. No serious adverse events occurred. Fragility fractures were markedly and durably reduced, amidst increased osteoanabolic BTM levels, BTA, and volumetric BMD. These findings indicate that glycocalyx editing effectuates MSC-based osteoporosis therapy and also refute notions that MSCs derived from older persons and/or diseased-tissue sites are biologically compromised.
中文摘要:间充质干/基质细胞(MSCs)具有骨再生能力,但其对骨骼疾病的治疗效力受限于骨归巢(「骨趋向性」)不佳。在临床前模型中,通过编辑MSC糖萼以强制表达唾液酸化Lewis X(sLeX),可纠正这一缺陷,从而赋予骨趋向性。我们开展了一项首次人体临床试验(ClinicalTrials.gov: NCT02566655),对十名晚期骨质疏松女性单次静脉输注糖萼编辑的自体骨髓来源MSCs。方案规定的评估持续2年,包括临床评估、影像学检查,以及骨转换标志物(BTMs)、骨组织面积(BTA)和骨密度(BMD)测量。此后,每名患者继续接受骨折与安全性监测超过3年。未发生严重不良事件。脆性骨折显著且持久减少,同时骨合成代谢BTM水平、BTA和体积BMD升高。这些结果说明糖萼编辑可实现基于MSC的骨质疏松治疗,也反驳了来源于高龄个体和/或病变组织部位的MSC生物学功能受损的观点。
基础研究 (3篇)
Postmenopausal osteoporosis (PMOP), driven primarily by estrogen deficiency, represents a major public health challenge. Although estrogen's anti-resorptive effects are well established, the direct osteogenic actions by which it regulates the osteogenic differentiation of mesenchymal stem cells (MSCs) remain poorly understood. This study aimed to elucidate a novel mechanism by which estrogen regulates osteogenic differentiation in MSCs and to identify key downstream molecular events. We employed single-cell RNA sequencing to profile the transcriptional landscape of osteoporotic MSCs. The pro-osteogenic effects of estradiol (E2) were validated in ovariectomized mice and primary mouse bone marrow-derived MSCs through in vitro differentiation assays and mitochondrial functional analyses. Downstream targets of estrogen receptor were identified by integrating CUT&Tag-seq with transcriptomic data and validated using conditional knockout mice. Protein interactions and phosphorylation sites were mapped via co-immunoprecipitation, mass spectrometry, site-directed mutagenesis, and mitochondrial morphology assays. Osteoporotic MSCs displayed concurrent impairments in osteogenic differentiation and mitochondrial function. E2 stimulated mitochondrial fission, enhanced maximal respiration, and induced DRP1 translocation to mitochondria. The combined evidence from our CUT&Tag-seq, RNA-seq, and the additional CUT&Tag-qPCR and ERα knockdown data supports the conclusion that Pdk4 is a direct transcriptional target of ERα. This finding is further corroborated by the compromised osteogenesis observed in conditional Pdk4 knockout mice. Mechanistically, PDK4 catalyzed MYH9 phosphorylation at serine 1943, thereby facilitating DRP1 recruitment to mitochondria and subsequent fission. Both pharmacological inhibition of PDK4 and introduction of the phosphorylation-deficient MYH9 S1943A mutant abolished the E2-induced effects. Notably, Pdk4 overexpression in ovariectomized mice reversed bone loss in the absence of exogenous estrogen. This study identifies an unrecognized ERα-PDK4-MYH9 signaling axis through which estrogen drives mitochondrial fission to promote osteogenic differentiation of MSCs. These findings expand the current understanding of estrogen's skeletal actions by revealing a pro-osteogenic effect on MSCs, and suggest PDK4 as a potential candidate for therapeutic exploration in PMOP.
中文摘要:绝经后骨质疏松(PMOP)主要由雌激素缺乏驱动,是重要的公共卫生挑战。雌激素的抗骨吸收作用已较明确,但其调控间充质干细胞(MSCs)成骨分化的直接成骨作用仍认识不足。本研究旨在阐明雌激素调控MSCs成骨分化的新机制并识别关键下游分子事件。我们采用单细胞RNA测序描绘骨质疏松MSCs的转录图谱。通过体外分化实验和线粒体功能分析,在去卵巢小鼠及原代小鼠骨髓来源MSCs中验证雌二醇(E2)的促成骨作用。整合CUT&Tag-seq与转录组数据识别雌激素受体的下游靶点,并用条件敲除小鼠验证。通过免疫共沉淀、质谱、定点突变和线粒体形态实验解析蛋白互作及磷酸化位点。骨质疏松MSCs同时存在成骨分化和线粒体功能受损。E2刺激线粒体分裂,增强最大呼吸,并诱导DRP1转位至线粒体。CUT&Tag-seq、RNA-seq以及补充的CUT&Tag-qPCR和ERα敲低数据共同支持Pdk4是ERα直接转录靶点的结论。条件性Pdk4敲除小鼠成骨受损进一步佐证该发现。机制上,PDK4催化MYH9在丝氨酸1943位点磷酸化,促进DRP1募集至线粒体并引发分裂。药理学抑制PDK4和引入磷酸化缺陷的MYH9 S1943A突变体均消除E2诱导的效应。Pdk4过表达在去卵巢小鼠中可在无外源雌激素情况下逆转骨丢失。本研究识别出一条此前未被认识的ERα-PDK4-MYH9信号轴,雌激素通过该轴驱动线粒体分裂以促进MSCs成骨分化。这些发现揭示雌激素对MSCs的促成骨作用,拓展了对雌激素骨骼作用的认识,并提示PDK4可作为PMOP治疗探索的潜在候选靶点。
Glucocorticoid-induced osteoporosis (GIOP) involves impaired bone remodeling, intestinal dysbiosis, and immune imbalance, which together limit the long-term benefit of conventional oral bisphosphonate therapy. Here, we report LpEVs@ALN, a probiotic extracellular vesicle-based oral nanoplatform constructed by loading alendronate (ALN) into Lacticaseibacillus paracasei-derived extracellular vesicles. LpEVs@ALN maintains vesicle integrity and epithelial compatibility, improves ALN retention under acidic exposure, and enables sustained ALN release at intestinal pH conditions. In dexamethasone-suppressed BMSCs, LpEVs@ALN enhances osteogenic differentiation, as evidenced by increased ALP activity and matrix mineralization. In zebrafish GIOP models, LpEVs@ALN improves cranial mineralization, new bone formation, scale regeneration, and locomotor/shoaling performance; accompanied by reduced inflammatory tone, improved ALP/RANKL-associated bone turnover readouts, and rebalanced oxidative-stress indices. Microbiome profiling shows recovery of richness/diversity and reduced Proteobacteria dominance, while scale RNA-seq reveals broad reversal of glucocorticoid-driven dysregulation toward pro-osteogenic and anti-inflammatory programs. Integrated correlation analysis further linked microbial remodeling with systemic and skeletal responses, suggesting involvement of the gut-immune-bone axis. Collectively, LpEVs@ALN alleviates GIOP by combining ALN-mediated bone protection with probiotic extracellular vesicle-associated regulation of intestinal and systemic homeostasis, highlighting its potential as an oral therapeutic strategy for GIOP.
中文摘要:糖皮质激素性骨质疏松(GIOP)涉及骨重建受损、肠道菌群失调和免疫失衡,这些因素共同限制了传统口服双膦酸盐治疗的长期获益。研究报告了LpEVs@ALN,一种基于益生菌细胞外囊泡构建的口服纳米平台,通过将阿仑膦酸钠(ALN)载入副干酪乳杆菌来源的细胞外囊泡而成。LpEVs@ALN保持囊泡完整性和上皮相容性,提高酸性暴露下ALN的保留,并在肠道pH条件下实现ALN持续释放。在地塞米松抑制的BMSCs中,LpEVs@ALN增强成骨分化,表现为ALP活性和基质矿化增加。在斑马鱼GIOP模型中,LpEVs@ALN改善颅骨矿化、新骨形成、鳞片再生以及运动/群游表现,同时伴随炎症水平降低、ALP/RANKL相关骨转换指标改善和氧化应激指标重新平衡。微生物组分析显示丰富度和多样性恢复,变形菌门优势降低,鳞片RNA-seq显示糖皮质激素驱动的广泛失调向促骨生成和抗炎程序逆转。整合相关性分析进一步将微生物重塑与全身及骨骼反应联系起来,提示肠-免疫-骨轴的参与。总体而言,LpEVs@ALN通过结合ALN介导的骨保护与益生菌细胞外囊泡相关的肠道及全身稳态调节来缓解GIOP,显示其作为GIOP口服治疗策略的潜力。
The contribution of polyol metabolism to pathological bone remodeling remains incompletely understood. Here, we examined its role in osteoclastogenesis and evaluated the skeletal effects of epalrestat, a clinically approved aldose reductase inhibitor. Exploratory single-cell analysis of two human femoral-head specimens suggested greater macrophage-associated polyol-pathway activity in the osteoporosis specimen. In primary bone marrow-derived macrophages, silencing of Akr1b3 and Sord produced opposing effects on osteoclast differentiation. Epalrestat suppressed RANKL-induced osteoclastogenesis and attenuated bone loss in diabetic, ovariectomy-induced, and inflammatory mouse models under early-intervention regimens. Mechanistic analyses showed improved NADPH/NADP⁺ and GSH/GSSG balance, reduced oxidative stress, and attenuated cytosolic and mitochondrial Ca²⁺ signals and Ca²⁺ oscillations. Genetic and osmotic-compensation experiments further supported a model in which intracellular sorbitol contributes to the osmotic regulation of Ca²⁺ oscillations. Additional findings included reduced inflammation in osteolysis and arthritis models, altered macrophage polarization, and partial preservation of bone marrow vascular features. Together, these findings connect glucose metabolism with redox and Ca²⁺ regulation during osteoclast differentiation and provide a rationale for further evaluation of epalrestat in skeletal disease.
中文摘要:多元醇代谢对病理性骨重塑的作用仍未完全明确。我们考察其在破骨细胞生成中的作用,并评估临床已批准的醛糖还原酶抑制剂依帕司他的骨骼效应。对两例人股骨头标本的探索性单细胞分析提示,骨质疏松标本中巨噬细胞相关的多元醇通路活性更高。在原代骨髓来源巨噬细胞中,沉默 Akr1b3 和 Sord 对破骨细胞分化产生相反影响。依帕司他在早期干预方案下抑制 RANKL 诱导的破骨细胞生成,并减轻糖尿病、卵巢切除诱导及炎症小鼠模型中的骨丢失。机制分析显示 NADPH/NADP⁺ 与 GSH/GSSG 平衡改善、氧化应激降低,胞质和线粒体 Ca²⁺ 信号及 Ca²⁺ 振荡减弱。遗传学和渗透压补偿实验进一步支持细胞内山梨醇参与 Ca²⁺ 振荡渗透调节的模型。其他发现包括骨溶解和关节炎模型中炎症减轻、巨噬细胞极化改变,以及骨髓血管特征的部分保留。这些结果将葡萄糖代谢与破骨细胞分化中的氧化还原和 Ca²⁺ 调控联系起来,并为在骨骼疾病中进一步评估依帕司他提供依据。
2骨关节炎/软骨 (4篇)
基础研究 (4篇)
Mesenchymal stem/stromal cells (MSCs) continue to drive innovation in regenerative medicine, yet the field is undergoing a critical evolution from the early concept of cellular engraftment to complex paracrine-mediated tissue repair. This review systematically evaluates the core scientific questions defining this transition, highlighting the latest advancements in MSC biology and the rapidly expanding therapeutic frontier of MSC-derived extracellular vesicles (MSC-EVs). We critically appraise recent progress in decoding MSC therapeutic mechanisms, specifically their profound capacity for immune modulation and microenvironmental remodeling. By synthesizing current findings across diverse and challenging clinical applications-encompassing oral tissue regeneration, osteoarthritis, and complex immune disorders-we provide expert insights into the discrepancies between promising preclinical data and variable clinical outcomes. Crucially, we address persistent translational bottlenecks, including inherent donor heterogeneity, manufacturing scalability, and the lack of standardized potency assays. It is our perspective that overcoming these limitations demands a strategic pivot towards precise cell-free MSC-EV therapies and advanced bioengineering strategies. Ultimately, this review highlights key directions for future research. By connecting basic mechanistic insights with clinical demands, we aim to accelerate the translation of effective MSC-based therapies.
中文摘要:间充质干/基质细胞(MSCs)持续推动再生医学创新,但该领域正经历关键演变:从早期细胞植入概念转向复杂的旁分泌介导组织修复。本综述系统评估界定这一转变的核心科学问题,重点介绍MSC生物学的最新进展以及MSC来源细胞外囊泡(MSC-EVs)快速拓展的治疗前沿。我们批判性评价近期在解析MSC治疗机制方面的进展,尤其是其强大的免疫调节与微环境重塑能力。通过整合口腔组织再生、骨关节炎及复杂免疫疾病等多样且具挑战性的临床应用中的现有发现,我们提供专家见解,分析有前景的临床前数据与多变临床结局之间的差异。更需关注的是,我们讨论持续存在的转化瓶颈,包括供者固有异质性、生产可扩展性以及标准化效力检测的缺乏。我们认为,克服这些局限需要战略转向精准无细胞MSC-EV疗法与先进生物工程策略。最终,本综述指出未来研究的关键方向。通过连接基础机制见解与临床需求,我们旨在加速有效MSC疗法的转化。
Synovitis is a central driver of osteoarthritis (OA) progression, yet the cellular and molecular mechanisms sustaining inflammatory circuits in the synovium remain incompletely understood. Through integrative analysis of time-resolved single-cell RNA sequencing in murine synovium and spatial transcriptomics of human OA tissues, we identified a pathogenic CD74+ macrophage subset that expands in OA and localizes at the synovial-cartilage interface. This subset exhibits a proinflammatory, nonclassical polarization and displays a metabolic dependency on glycolysis. Multiomics and mechanistic studies revealed that CD74 interacts with the glycolytic enzyme enolase 2 (ENO2). This interaction orchestrates a feed-forward signaling axis wherein CD74/ENO2 facilitates the nuclear translocation of hypoxia-inducible factor 1-α (HIF-1α)/β-catenin dimers, which coactivate glycolytic and inflammatory gene programs, thereby sustaining a metabolically driven inflammatory state. Genetic ablation of CD74 in myeloid cells or its pharmacological blockade mitigated synovitis and cartilage degradation in murine OA models. To translate this axis therapeutically, we developed synovium-targeted cationic lipid nanoparticles decorated with MIF-mimetic peptides (PcLNPs) for the delivery of CD74 siRNA. Intra-articular administration of PcLNPs efficiently targeted CD74+ macrophages, attenuated their inflammatory and glycolytic phenotypes, and ameliorated murine OA progression in vivo. Our findings establish the CD74/ENO2/HIF-1α/β-catenin axis as a critical integrator of metabolic reprogramming and inflammation in OA synovitis and present a potential targeted nanotherapeutic strategy for disease modification.
中文摘要:滑膜炎是骨关节炎(OA)进展的核心驱动因素,但维持滑膜炎症回路的细胞与分子机制仍未被充分理解。通过对小鼠滑膜的时间分辨单细胞RNA测序数据与人OA组织的空间转录组进行整合分析,我们识别出一个致病性CD74+巨噬细胞亚群,该亚群在OA中扩增并定位于滑膜-软骨交界处。该亚群呈现促炎性、非经典极化状态,并表现出对糖酵解的代谢依赖。多组学与机制研究显示,CD74与糖酵解酶烯醇化酶2(ENO2)相互作用。这一相互作用组织起前馈信号轴:CD74/ENO2促进缺氧诱导因子1-α(HIF-1α)/β-连环蛋白二聚体核转位,二者共同激活糖酵解与炎症基因程序,从而维持代谢驱动的炎症状态。髓系细胞中CD74的遗传性缺失或其药理学阻断可减轻小鼠OA模型中的滑膜炎与软骨降解。为实现该信号轴的治疗转化,我们开发了滑膜靶向的阳离子脂质纳米颗粒(PcLNPs),其表面修饰MIF模拟肽,用于递送CD74 siRNA。关节腔内给予PcLNPs可高效靶向CD74+巨噬细胞,减弱其炎症与糖酵解表型,并在体内改善小鼠OA进展。研究结果确立CD74/ENO2/HIF-1α/β-连环蛋白轴是OA滑膜炎中代谢重编程与炎症的关键整合者,并提供一种潜在的靶向纳米治疗策略以改变疾病进程。
Healthy articular cartilage maintains ultralow friction through the lipid/hyaluronic acid/lubricin complex lubrication layer, in which the zwitterionic lipids mediate lubrication and the hyaluronic acid and lubricin anchor to cartilage matrix. However, in osteoarthritis this lubrication system is progressively degraded, leading to increased cartilage wear and joint dysfunction. Therefore, early and lubrication-based intervention is urgently needed. Here we present biomimetic polyzwitterionic coacervates (pZCOs) that recapitulate both the lubrication and cartilage-binding functionalities of the natural boundary lubrication layer. pZCOs exhibit strong binding affinity to fibronectin, establish a stable and ultralow-friction lubrication layer on the cartilage surface, facilitate the sustained release of anti-inflammatory drugs, and preserve the viability and anti-inflammatory paracrine secretion of encapsulated mesenchymal stem cells. In both rat and mini-pig models of osteoarthritis, intra-articular administration of drug/MSC-laden pZCOs effectively reduces cartilage degradation, suppresses inflammation and promotes cartilage integrity, outperforming clinical hyaluronic acid lubricants in lubrication performance, in vivo retention and therapeutic efficacy. These findings highlight the translational potential of engineered biomimetic coacervates as next-generation joint lubricants for integrated management of osteoarthritis.
中文摘要:健康关节软骨通过脂质/透明质酸/润滑素复合润滑层维持超低摩擦,其中两性离子脂质介导润滑,透明质酸和润滑素锚定于软骨基质。但在骨关节炎中,该润滑系统逐步退化,导致软骨磨损增加和关节功能障碍。因此亟需早期、基于润滑的干预。我们提出仿生聚两性离子凝聚体(pZCOs),其重现天然边界润滑层的润滑和软骨结合功能。pZCOs与纤连蛋白具有强结合亲和力,在软骨表面建立稳定且超低摩擦的润滑层,促进抗炎药物持续释放,并维持包封间充质干细胞的活力和抗炎旁分泌作用。在大鼠和小型猪骨关节炎模型中,关节内注射载药/载间充质干细胞的pZCOs有效减少软骨降解、抑制炎症并促进软骨完整性,在润滑性能、体内滞留和治疗效果方面优于临床透明质酸润滑剂。这些发现凸显工程化仿生凝聚体作为下一代关节润滑剂用于骨关节炎综合管理的转化潜力。
Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase responsible for H3K27 trimethylation, has emerged as a potential therapeutic target in osteoarthritis (OA). However, its contribution to the multicellular mechanisms driving joint degeneration and pain remains poorly understood. Here, we investigated the effects of pharmacological EZH2 inhibition in a pain-relevant murine OA model and explored its cellular and molecular consequences across OA-associated cell populations. OA was induced in mice by intra-articular monosodium iodoacetate (MIA) injection followed by local administration of the EZH2 inhibitor EPZ-6438. Joint pathology and pain-related behaviors were assessed by histological and functional analyses. Mechanistic studies were performed in primary human OA fibroblast-like synoviocytes and bone marrow-derived cells using targeted gene expression analyses, proteomics and ChIP-seq approaches. EZH2 inhibition reduced cartilage damage, synovial inflammation and pain-related behavioral alterations in vivo. In OA synoviocytes, EPZ-6438 decreased the expression of inflammatory, catabolic and pain-associated mediators while promoting autophagy-related responses. Proteomic and ChIP-seq analyses revealed EZH2-dependent regulation of inflammatory pathways, cellular homeostasis and neuronal-associated processes, including axon guidance-related pathways. ChIP-seq further identified inflammation-dependent EZH2 recruitment to promoters of neurodevelopmental regulators, including PAX6, suggesting a potential contribution of EZH2 to neuronal-associated mechanisms in OA. In addition, EZH2 inhibition reduced macrophage inflammatory activation and osteoclast differentiation. Together, these findings identify EZH2 as a candidate epigenetic regulator linking inflammatory, neuroimmune and osteoimmune pathways across the osteoarthritic joint. Targeting EZH2 may represent a therapeutic strategy to simultaneously modulate joint inflammation, remodeling and pain-associated pathways.
中文摘要:增强子zeste同源物2(EZH2)是一种负责H3K27三甲基化的组蛋白甲基转移酶,已成为骨关节炎(OA)的潜在治疗靶点。但它在驱动关节退变和疼痛的多细胞机制中的作用仍不清楚。研究在疼痛相关的鼠OA模型中考察药物抑制EZH2的效果,并探索其对OA相关细胞群体的细胞与分子影响。小鼠关节腔内注射碘乙酸钠(MIA)诱导OA,随后局部给予EZH2抑制剂EPZ-6438。通过组织学和功能分析评估关节病理与疼痛相关行为。机制研究在原发性人OA成纤维样滑膜细胞和骨髓来源细胞中进行,采用靶向基因表达分析、蛋白质组学和ChIP-seq方法。抑制EZH2在体内减轻软骨损伤、滑膜炎症和疼痛相关行为改变。在OA滑膜细胞中,EPZ-6438降低炎症性、分解代谢性和疼痛相关介质的表达,同时促进自噬相关反应。蛋白质组学和ChIP-seq分析显示EZH2依赖性地调控炎症通路、细胞稳态和神经元相关过程,包括轴突导向相关通路。ChIP-seq进一步发现炎症依赖性的EZH2募集到神经发育调节因子(包括PAX6)的启动子,提示EZH2可能参与OA中的神经元相关机制。抑制EZH2还降低巨噬细胞炎症活化和破骨细胞分化。这些结果将EZH2确定为候选表观遗传调控因子,连接骨关节炎关节中的炎症、神经免疫和骨免疫通路。靶向EZH2可能成为一种同时调节关节炎症、重塑和疼痛相关通路的治疗策略。
3关节外科/置换 (2篇)
基础研究 (2篇)
Acid mine drainage (AMD) from karst sulfide mines threatens regional groundwater security, yet water-rock-pollutant coupling across heterogeneous runoff media remains poorly understood. Using hydrogeological, hydrochemical and isotopic data, we examined four water types-tailings-pond water (M-type), fracture-spring and conduit water (S-type, G-type) and surface river water (R-type)-along fracture-conduit runoff zones in an AMD-affected karst watershed during the August 2024 wet season. All waters were circumneutral to weakly alkaline, carbonate-neutralized AMD-affected waters, not acidic leachate. Isotopes (δ²H-H₂O, δ¹⁸O-H₂O, δ³⁴S-SO₄ and δ¹⁸O-SO₄) and hydrochemistry showed that M water was dominated by sulfuric-acid dissolution, S-type water by mixed carbonic-sulfuric-acid dissolution, R-type water by coexisting multi-acid dissolution and G-type water by carbonic-acid dissolution. S-type water showed stronger apparent bidirectional AMD buffering than R/G-type water, although dilution and immobilization could not be distinguished. Isotope patterns were consistent with preferential bacterial sulfate reduction (BSR) in fractures, one of several interpretations pending microbiological verification. Sulfide oxidation elevated dissolved metals in M-type water; dilution reduced them downstream in R-type water. S-type water likely attenuated metals through carbonate buffering and weakly reducing conditions, with a possible unverified BSR contribution; G-type water buffered mainly through carbonate dissolution. These findings support karst AMD prevention and control.
中文摘要:岩溶硫化物矿山的酸性矿山排水(AMD)威胁区域地下水安全,但异质径流介质中水—岩—污染物耦合仍认识不足。利用水文地质、水化学和同位素数据,考察了2024年8月丰水期受AMD影响的岩溶流域沿裂隙—管道径流带的四类水体:尾矿库水(M型)、裂隙泉水与管道水(S型、G型)以及地表河水(R型)。所有水体均为中性至弱碱性、受碳酸盐中和的AMD影响水体,并非酸性浸出液。同位素(δ²H-H₂O、δ¹⁸O-H₂O、δ³⁴S-SO₄、δ¹⁸O-SO₄)与水化学表明,M型水以硫酸溶解为主,S型水为碳酸—硫酸混合溶解,R型水为多酸共存溶解,G型水以碳酸溶解为主。S型水表现出比R/G型水更强的表观双向AMD缓冲能力,但稀释与固定作用尚不能区分。同位素特征与裂隙中优先发生的细菌硫酸盐还原(BSR)相符,这是有待微生物学验证的若干解释之一。硫化物氧化提高了M型水中溶解态金属,稀释使R型水下游金属降低。S型水可能通过碳酸盐缓冲和弱还原条件衰减金属,并可能有尚未验证的BSR贡献;G型水主要通过碳酸盐溶解缓冲。这些发现支持岩溶AMD防治。
The Human Cell Atlas (HCA) has fundamentally changed the way biologists describe human tissues. However, its greatest promise for musculoskeletal (MSK) practitioners lies ahead: to convert cellular maps into clinically actionable knowledge. MSK diseases are common, heterogeneous, and often insufficiently stratified by current diagnostic labels. The same label, such as rheumatoid arthritis, can conceal distinct cellular mechanisms, tissue niches, and therapeutic vulnerabilities. Conversely, apparently different disorders such as tendinopathy or fibrotic capsulitis can share convergent stromal, immune, vascular, or neuronal programmes. A MSK-HCA therefore should not be conceived as a passive reference catalogue. It should be 'medicalised': designed from the outset to connect tissue atlases with clinical phenotypes, imaging, biospecimens, genetic risk, biomarkers, perturbation experiments, and interventional trials. In this review, we describe how single-cell, single-nucleus, spatial, and multiomic approaches are beginning to map MSK tissues from development to ageing and from health to disease. We highlight examples in embryonic skeletal development, bone marrow, muscle ageing, osteoarthritis, rheumatoid arthritis, tendon disease, and inflammatory fibrosis and show how these data can reframe disease taxonomy around pathogenic cell states rather than organ-level labels alone. We propose a translational roadmap in which atlases define healthy reference coordinates, identify disease-enriched cell states, nominate biomarkers and therapeutic targets, and then learn from clinical trial outcomes. For clinicians, the MSK-HCA offers a route to mechanism-led diagnosis and patient stratification; for scientists, it provides a shared coordinate system for testing how genes, cells, and tissue microenvironments generate disease. Medicalising the HCA could make cellular medicine a practical foundation for precision rheumatology and regenerative MSK therapy.
中文摘要:人类细胞图谱(HCA)已经改变了生物学家描述人体组织的方式,但其对肌肉骨骼(MSK)从业者最大的前景仍在前面:把细胞图谱转化为可在临床落地的知识。MSK疾病常见、异质性强,现有诊断标签往往分层不足。同一个标签如类风湿关节炎,可能掩盖不同的细胞机制、组织微环境和治疗脆弱性。相反,看似不同的疾病如肌腱病或纤维化关节囊炎,可能共享趋同的基质、免疫、血管或神经程序。因此,MSK-HCA不应被设想为被动的参考目录,而应被「医学化」:从设计之初就连接组织图谱与临床表型、影像、生物样本、遗传风险、生物标志物、扰动实验和干预试验。这篇综述描述单细胞、单核、空间和多组学方法如何开始绘制MSK组织从发育到衰老、从健康到疾病的过程。文中列举胚胎骨骼发育、骨髓、肌肉衰老、骨关节炎、类风湿关节炎、肌腱病和炎性纤维化中的例子,说明这些数据如何围绕致病性细胞状态而非仅器官层面标签重新构建疾病分类。文中提出一条转化路线图:图谱定义健康参考坐标,识别疾病富集的细胞状态,提名生物标志物和治疗靶点,再从临床试验结局中学习。对临床医生,MSK-HCA提供通向机制导向诊断和患者分层的路径;对科学家,它提供共享坐标系统,用于检验基因、细胞和组织微环境如何产生疾病。把HCA医学化,可使细胞医学成为精准风湿病学和再生MSK治疗的实际基础。
4骨代谢/发育 (1篇)
基础研究 (1篇)
Bone development, homeostasis, and regeneration are governed by complex, dynamic gene regulatory programs, and these processes are disrupted in numerous skeletal diseases. The epigenetic landscape-particularly chromatin accessibility-dictates transcription factor binding and gene expression, which fundamentally shape bone cell fate and function. In recent years, single-cell chromatin accessibility technologies, most notably single-cell assay for transposase-accessible chromatin using sequencing (scATAC-seq), have revolutionized bone epigenome research and enabled single-cell resolution dissection of the skeletal system. This review summarizes recent progress in single-cell chromatin accessibility studies in bone biology, and systematically outlines chromatin-accessibility changes in skeletal development, diseases, and regeneration. We introduce cutting-edge single-cell epigenomic mapping technologies, their bone tissue-specific adaptations, and analytical frameworks for multi-omics data integration. These approaches reveal key biological findings: the identification of bone-resident subpopulations and lineage hierarchies, dynamic enhancer landscapes during osteoblast/chondrocyte differentiation, cellular bases of diseases such as osteoporosis and osteoarthritis, and novel mechanisms of bone tumorigenesis. Moreover, we discuss cross-applications of genomics and functional research, including mapping of disease-associated regulatory elements and emerging epigenome-editing strategies. Finally, we address current challenges, outline future directions, and envision the integration of single-cell epigenomics in precision orthopedics and regenerative medicine.
中文摘要:骨骼发育、稳态维持与再生受复杂且动态的基因调控程序支配,这些过程在多种骨骼疾病中发生紊乱。表观遗传景观,尤其是染色质可及性,决定转录因子结合与基因表达,并从基础层面塑造骨细胞命运和功能。近年来,单细胞染色质可及性技术,尤其是单细胞转座酶可及染色质测序(scATAC-seq),推动了骨表观基因组研究,使骨骼系统能够在单细胞分辨率下被解析。本综述总结单细胞染色质可及性研究在骨生物学中的近期进展,系统梳理骨骼发育、疾病与再生中的染色质可及性变化。文中介绍前沿单细胞表观基因组图谱技术、其在骨组织中的适配方法以及多组学数据整合分析框架。这些方法揭示了若干关键生物学发现:骨内驻留细胞亚群与谱系层级的鉴定,成骨细胞和软骨细胞分化过程中的动态增强子景观,骨质疏松与骨关节炎等疾病的细胞基础,以及骨肿瘤发生的新机制。综述还讨论基因组学与功能研究的交叉应用,包括疾病相关调控元件的图谱绘制和新兴表观基因组编辑策略。当前挑战、未来方向以及单细胞表观基因组学在精准骨科与再生医学中的整合应用也在文中得到讨论。
5运动医学/关节镜 (1篇)
临床研究 (1篇)
Psychological readiness is increasingly recognized as a critical determinant of return to sport (RTS) and return to preinjury level (RTPre) of sport after anterior cruciate ligament (ACL) reconstruction. Functional outcomes are also relevant. However, the clinical significance of psychological readiness and functional outcomes may vary depending on the postoperative time point, and the association of psychological readiness and functional outcomes with RTS may be temporal. This systematic review and meta-analysis aimed to evaluate the temporal association of psychological readiness and functional outcomes with RTS at different postoperative time points (≤6 months, <6-12 months, >12 months) after ACL reconstruction. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO CRD42025630743), 6 databases (MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, Web of Science Core Collection, and Scopus) were searched from January 1st, 2008 to April 1st, 2026. Data on psychological measures (ACL-Return to Sport after Injury (ACL-RSI), Knee Self-Efficacy Scale (K-SES), Tampa Scale for Kinesiophobia (TSK)), functional outcomes (International Knee Documentation Committee (IKDC), Knee Injury and Osteoarthritis Outcome Score (KOOS), Limb Symmetry Index (LSI) for knee flexion strength (FLEX-LSI), knee extension strength (EXT-LSI), and single-leg hop distance (SH-LSI)) were extracted from all eligible studies comparing these outcomes between RTS and non-RTS groups, as well as RTPre and non-RTPre groups following primary ACL reconstruction. Effect sizes were pooled as mean differences (continuous variable) or risk ratios (dichotomous variable). Subgroup analyses were stratified by postoperative follow-up time points: ≤6 months, >6-12 months, and >12 months. A total of 25 studies comprising 7174 patients were included. Overall, the RTS rate was 79.3%, whereas the RTPre rate was 44.1%. The RTPre group exhibited significantly higher ACL-RSI scores than the non-RTPre group, and intergroup difference in ACL-RSI widened progressively over time following ACL reconstruction (≤6 months: mean difference (MD) = 16.09, 95% confidence interval (95%CI): 9.13-23.05; >6-12 months: MD = 18.64, 95%CI: 14.64-22.63; >12 months: MD = 27.07, 95%CI: 22.37-31.76). Similar patterns were observed in the comparison of RTS and non-RTS groups. Compared with the non-RTS group, the RTS group showed higher K-SES scores (MD = 1.27, 95%CI: 1.06-1.87; p < 0.0001) and reduced kinesiophobia (TSK/TSK-11, standardized mean difference (SMD) = -1.15, 95%CI: -2.10 to -0.19, p = 0.02). The RTS group also demonstrated superior functional outcomes vs. the non-RTS group, including IKDC (MD = 7.52, 95%CI: 5.85-9.19), KOOS-Sport/Rec (MD = 11.32, 95%CI: 8.84-13.81), KOOS-quality of life (QoL) (MD = 13.97, 95%CI: 10.83-17.10), EXT-LSI (MD = 7.48%, 95%CI: 2.69-12.26), FLEX-LSI (MD = 3.67%, 95%CI: 0.91-6.43), SH-LSI (MD = 2.96%, 95%CI: 1.77-4.16), though IKDC differences remained below established minimal clinically important difference thresholds. Psychological readiness assessed via the ACL-RSI is important for RTS evaluation after ACL reconstruction. Our analyses uniquely reveal widening between-group gaps in psychological readiness at later recovery stages, with minimal temporal changes in functional differences. Longitudinal monitoring and serial ACL-RSI evaluation across varied postoperative phases is recommended alongside functional assessments to support RTS decision-making.
中文摘要:心理准备度日益被视为前交叉韧带重建后重返运动和重返伤前运动水平的关键决定因素,功能结局同样相关。心理准备度和功能结局的临床意义可能随术后时间点而变化,其与重返运动的关联可能具有时间性。该系统综述与荟萃分析旨在评估前交叉韧带重建后不同术后时间点(≤6个月、>6-12个月、>12个月)心理准备度和功能结局与重返运动的时间关联。按照系统综述和荟萃分析优先报告条目(PRISMA)指南(PROSPERO CRD42025630743),检索MEDLINE、Embase、Cochrane对照试验中心注册库(CENTRAL)、CINAHL、Web of Science核心合集和Scopus共6个数据库,时间范围为2008年1月1日至2026年4月1日。从所有符合条件的研究中提取心理测量指标(ACL重返运动后损伤量表ACL-RSI、膝关节自我效能感量表K-SES、坦帕恐动症量表TSK)和功能结局(国际膝关节文献委员会IKDC评分、膝关节损伤和骨关节炎结局评分KOOS、膝关节屈肌力量肢体对称指数FLEX-LSI、伸肌力量肢体对称指数EXT-LSI、单腿跳跃距离肢体对称指数SH-LSI)数据,这些研究比较初次前交叉韧带重建后重返运动组与非重返运动组以及重返伤前水平组与非重返伤前水平组的上述结局。效应量按连续变量的均数差或二分类变量的风险比合并。亚组分析按术后随访时间点分层:≤6个月、>6-12个月和>12个月。共纳入25项研究、7174例患者。总体重返运动率为79.3%,重返伤前水平率为44.1%。重返伤前水平组的ACL-RSI评分显著高于非重返伤前水平组,且ACL-RSI的组间差异随前交叉韧带重建后时间推移逐渐扩大(≤6个月:均数差MD=16.09,95%置信区间95%CI:9.13-23.05;>6-12个月:MD=18.64,95%CI:14.64-22.63;>12个月:MD=27.07,95%CI:22.37-31.76)。重返运动组与非重返运动组比较也观察到相似模式。与非重返运动组相比,重返运动组K-SES评分更高(MD=1.27,95%CI:1.06-1.87;p < 0.0001),恐动症程度更低(TSK/TSK-11,标准化均数差SMD=-1.15,95%CI:-2.10至-0.19,p=0.02)。重返运动组的功能结局也优于非重返运动组,包括IKDC(MD=7.52,95%CI:5.85-9.19)、KOOS运动/娱乐(MD=11.32,95%CI:8.84-13.81)、KOOS生活质量(MD=13.97,95%CI:10.83-17.10)、EXT-LSI(MD=7.48%,95%CI:2.69-12.26)、FLEX-LSI(MD=3.67%,95%CI:0.91-6.43)、SH-LSI(MD=2.96%,95%CI:1.77-4.16),但IKDC差异仍低于已建立的最小临床重要差异阈值。通过ACL-RSI评估的心理准备度对前交叉韧带重建后重返运动评价具有重要性。该分析独特显示,心理准备度的组间差距在恢复后期扩大,而功能差异随时间变化很小。建议在不同术后阶段结合功能评估进行纵向监测和连续ACL-RSI评估,以支持重返运动决策。
6创伤骨科 (1篇)
临床研究 (1篇)
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have demonstrated cardiorenal benefits in individuals with type 2 diabetes, but safety data in older adults remain limited. We evaluated the real-world safety of SGLT2is compared with dipeptidyl peptidase 4 inhibitors (DPP-4is) among individuals aged ≥75 years with type 2 diabetes. We conducted a population-based, active-comparator, new-user cohort study using administrative health databases from British Columbia, Canada. We included individuals aged ≥75 years with type 2 diabetes initiating SGLT2is or DPP-4is between 1 January 2021 and 31 December 2023. Primary outcomes were infection, diabetic ketoacidosis, acute kidney injury, fall, fracture, and all-cause hospitalization. Cox regression with propensity score-based standardized mortality ratio weighting was used to estimate hazard ratios (HRs). The study included 4,997 SGLT2i initiators (median age, 79 years; 37% women) and 1,289 DPP-4i initiators (median age, 82 years; 50% women). Compared with DPP-4i initiation, SGLT2i initiation was associated with lower risks of acute kidney injury (HR 0.76, 95% CI 0.60-0.95) and all-cause hospitalization (HR 0.87, 95% CI 0.77-0.98), with no difference in risk of infection. No differences were observed in risk of diabetic ketoacidosis, falls, or fractures, although CIs were compatible with both benefit and harm. In individuals aged ≥75 years with type 2 diabetes, SGLT2i initiation was not associated with increased risk of harm compared with DPP-4i initiation, although estimates were imprecise for some outcomes. These findings may support consideration of SGLT2is as a treatment option in this population.
中文摘要:钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)已在2型糖尿病人群中显示心肾获益,但老年人群的安全性数据仍有限。我们评估了≥75岁2型糖尿病患者中SGLT2i与二肽基肽酶4抑制剂(DPP-4i)相比的真实世界安全性。研究采用加拿大不列颠哥伦比亚省行政健康数据库,开展基于人群、活性对照、新用户队列研究,纳入2021年1月1日至2023年12月31日期间开始SGLT2i或DPP-4i治疗的≥75岁2型糖尿病患者。主要结局为感染、糖尿病酮症酸中毒、急性肾损伤、跌倒、骨折和全因住院。采用Cox回归,并以基于倾向评分的标准化死亡比加权估计风险比(HR)。研究纳入4,997例SGLT2i起始者(中位年龄79岁;女性37%)和1,289例DPP-4i起始者(中位年龄82岁;女性50%)。与开始DPP-4i治疗相比,开始SGLT2i治疗与急性肾损伤风险较低(HR 0.76,95% CI 0.60-0.95)和全因住院风险较低(HR 0.87,95% CI 0.77-0.98)相关,感染风险无差异。糖尿病酮症酸中毒、跌倒或骨折风险未见差异,但置信区间与获益和危害均相容。在≥75岁2型糖尿病患者中,与开始DPP-4i治疗相比,开始SGLT2i治疗未伴随危害风险增加,尽管部分结局的估计不精确。这些发现可能支持将该人群中的SGLT2i视为治疗选择。
7骨折/创伤 (1篇)
临床研究 (1篇)
Acute stress disorder (ASD) is a common and debilitating psychological sequela following traumatic fracture surgery, adversely affecting recovery and predicting chronic posttraumatic stress disorder. Effective pharmacological prevention strategies are currently lacking. To evaluate the efficacy and safety of a single preoperative dose of intranasal oxytocin for the prevention of screening-positive probable ASD in patients undergoing traumatic fracture surgery. This single-center, prospective, double-blind, placebo-controlled randomized clinical trial was conducted at the General Hospital of Western Theater Command in China. From April 2024 to April 2025, adult patients scheduled for traumatic fracture surgery were enrolled and randomized. Participants were randomly assigned in a 1:1 ratio to either receive intranasal oxytocin, 40 IU, or an equivalent volume of intranasal saline placebo 10 minutes before the induction of anesthesia. The primary outcome was the cumulative incidence of a first screening-positive probable ASD within 3 days postoperatively, defined by a Stanford Acute Stress Reaction Questionnaire (SAS-RQ) score of 40 or higher. Key secondary outcomes included the Connor-Davidson Resilience Scale (CD-RISC), the Hospital Anxiety and Depression Scale (HADS), and salivary malondialdehyde, cortisol, and superoxide dismutase levels. A total of 328 patients were randomized (164 to the saline group and 164 to the oxytocin group) and included in the intention-to-treat analysis. The median (IQR) age of all participants was 50 (34-57) years; 210 participants (64.0%) were male, and 118 participants (36.0%) were female. The 3-day cumulative incidence of screening-positive probable ASD was 26 of 164 (15.9%) in the oxytocin group vs 50 of 164 (30.5%) in the saline group (risk difference, -14.6 percentage points [pp]; 95% CI, -23.5 to -5.5 pp; risk ratio, 0.52; 95% CI, 0.34-0.79). In the prespecified Cox model, preoperative oxytocin was associated with a lower hazard of a positive screening result during follow-up (adjusted hazard ratio, 0.45; 95% CI, 0.27-0.75). Exploratory analyses suggested improved psychological outcomes and directionally consistent alterations in stress biomarker trajectories. No serious adverse events were observed. In this randomized clinical trial, preoperative intranasal oxytocin is associated with a lower cumulative incidence of probable ASD after traumatic fracture surgery. These findings suggest that intranasal oxytocin may represent a feasible perioperative preventive strategy; however, these exploratory mechanistic insights and long-term safety profile warrant further investigation. Chinese Clinical Trial Registry Identifier: ChiCTR2400082612.
中文摘要:创伤性骨折手术后急性应激障碍(ASD)是常见且可致残的心理后遗症,影响康复并预测慢性创伤后应激障碍,目前缺乏有效药物预防策略。评价术前单次鼻内催产素预防创伤性骨折手术患者筛查阳性可能ASD的疗效与安全性。这项单中心、前瞻性、双盲、安慰剂对照随机临床试验在中国西部战区总医院开展。2024年4月至2025年4月纳入并随机分配拟行创伤性骨折手术的成年患者。参与者按1:1随机接受鼻内催产素40 IU或等体积鼻内生理盐水安慰剂,于麻醉诱导前10分钟给药。主要结局为术后3天内首次筛查阳性可能ASD的累积发生率,定义为斯坦福急性应激反应问卷(SAS-RQ)评分40分及以上。关键次要结局包括康纳-戴维森韧性量表(CD-RISC)、医院焦虑抑郁量表(HADS)以及唾液丙二醛、皮质醇和超氧化物歧化酶水平。共328例患者被随机分配(生理盐水组164例,催产素组164例)并纳入意向性治疗分析。所有参与者年龄中位数(IQR)为50(34-57)岁;男性210例(64.0%),女性118例(36.0%)。筛查阳性可能ASD的3天累积发生率在催产素组为26/164(15.9%),生理盐水组为50/164(30.5%)(风险差-14.6个百分点[pp];95% CI,-23.5至-5.5 pp;风险比0.52;95% CI,0.34-0.79)。在预设Cox模型中,术前催产素与随访期间筛查阳性风险较低相关(校正风险比0.45;95% CI,0.27-0.75)。探索性分析提示心理结局改善,应激生物标志物轨迹出现方向一致的改变。未观察到严重不良事件。在这项随机临床试验中,术前鼻内催产素与创伤性骨折手术后可能ASD累积发生率较低相关。这些发现提示鼻内催产素可能是一种可行的围手术期预防策略;但这些探索性机制见解和长期安全性仍需进一步研究。中国临床试验注册中心注册号:ChiCTR2400082612。